title: Treatment of membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Niigata Research Group of Glomerulonephritis and Nephrotic Syndrome.
abstract: OBJECTIVE
  Interferon has been used as a new therapeutic agent for glomerulonephritis since a manifest relationship between membranoproliferative glomerulonephritis (MPGN) and hepatitis C virus (HCV) infection was documented. However, several side effects and rebound phenomenon have been significant problems. We retrospectively evaluated the therapeutic effect and safety of the standard treatment with steroids and/or immunosuppressive agents for MPGN patients with an HCV infection.
  
  
  METHODS
  Remission and renal survival rates as well as clinical and histological data were compared between MPGN groups with or without an HCV infection. In addition, the hepatic function was followed-up after the treatment.
  
  
  METHODS
  The subjects were 42 biopsy proven MPGN patients. Seven were positive for an HCV infection. Secondary causes of MPGN excluding an HCV infection were omitted. Most patients were treated with steroids and/or immunosuppressive agents.
  
  
  RESULTS
  The mean age of the MPGN patients with an HCV infection was significantly higher than that of those without an HCV infection. The renal function and the interstitial change of the former group were significantly worse than those of the latter. Nevertheless, remission and renal survival rates were not significantly different between the two groups. None in the HCV positive MPGN group showed an impairment of hepatic function during the clinical course. However, 2 subjects died from severe pneumonia during the treatment.
  
  
  CONCLUSIONS
  The standard treatment with steroids and/or immunosuppressive agents did not reveal a statistical difference in the therapeutic efficacy between MPGN patients with or without an HCV infection. However, some in the former group showed a poor prognosis.
authors.affiliation: Department of Medicine (II), Niigata University School of Medicine.
authors.forename: S
authors.initials: S
authors.lastname: Nishi
authors.forename: M
authors.initials: M
authors.lastname: Ueno
authors.forename: H
authors.initials: H
authors.lastname: Shimada
authors.forename: Y
authors.initials: Y
authors.lastname: Oosawa
authors.forename: N
authors.initials: N
authors.lastname: Iino
authors.forename: S
authors.initials: S
authors.lastname: Iguchi
authors.forename: R
authors.initials: R
authors.lastname: Karasawa
authors.forename: H
authors.initials: H
authors.lastname: In
authors.forename: S
authors.initials: S
authors.lastname: Kawashima
authors.forename: N
authors.initials: N
authors.lastname: Saito
authors.forename: N
authors.initials: N
authors.lastname: Imai
authors.forename: K
authors.initials: K
authors.lastname: Saito
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Arakawa
authors.forename: F
authors.initials: F
authors.lastname: Gejyo
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001706:Biopsy; D004359:Drug Therapy, Combination; D005260:Female; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D005938:Glucocorticoids / Q000627:therapeutic use*; D006526:Hepatitis C / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007677:Kidney Function Tests; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors